RB1CC1 and p62/SQSTM1 abnormalities in human carcinogenesis, and their utilities on clinical application
| Project/Area Number |
24659272
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
CHANO Tokuhiro 滋賀医科大学, 医学部, 准教授 (40346028)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 腫瘍検査 / p62/SQSTM1 / RB1CC1 / Nrf2 / GSH |
|---|
| Research Abstract |
Staining of p62/SQSTM1 and RB1CC1 was scored by using a tissue microarray of lung cancers. RB1CC1 is expressed only in the cytoplasm of lung cancers, suggesting poor prognosis of lung cancers. p62/SQSTM1 accumulation was further associated with the worse survival, especially the worst in the cases with both expressions of p62/SQSTM1 and RB1CC1. p62/SQSTM1 could become a biomarker of worse prognosis in lung cancer cases.
In oral squamous cell carcinomas, p62/SQSTM1 contributed to induce glutathione in oral carcinoma cells, and to cause a resistance to radiation therapy. Clinico-pathological detection of p62/SQSTM1 accumulation could predict poor prognosis, and could be a new biomarker in the cases of oral squamous cell carcinoma.
|
Report
(3 results)
Research Products
(14 results)
